<p>药明康德（NASDAQ:DVAX - 获取免费报告）于周三发布了季度财报。这家生物制药公司报告本季度每股收益（EPS）为 0.21 美元，超出分析师一致预期的 0.14 美元，超出幅度为 0.07 美元，Zacks 报道。该公司本季度的收入为 9488 万美元，而一致预期为 9400 万美元。药明康德的股本回报率为 5.10%，净利润率为-16.67%。</p>
<p>获取 <strong>药明康德</strong> 的提醒：</p>
<h2>药明康德股票表现</h2>
<p>周三，NASDAQ DVAX 在交易时段上涨 0.25 美元，达到 10.30 美元。该股票交易量为 2,378,061 股，而其平均交易量为 1,977,836 股。药明康德的 12 个月低点为 9.20 美元，12 个月高点为 14.63 美元。该股票的 50 日移动平均为 9.99 美元，200 日移动平均为 10.28 美元。公司的市值为 12.1 亿美元，市盈率为-22.39，贝塔值为 1.09。公司的速动比率为 6.01，流动比率为 6.65，债务股本比率为 0.45。</p>
<h2>药明康德的内部交易</h2>
<p>在其他药明康德的新闻中，董事 Scott Dunseth Myers 于 8 月 22 日（星期五）购买了 3,800 股该公司的股票。该股票的平均购买价格为每股 10.82 美元，总价值为 41,116.00 美元。购买后，该董事在公司持有 35,004 股，估值约为 378,743.28 美元。这代表其持股比例增加了 12.18%。该交易已在向 SEC 提交的文件中披露，相关文件可通过 SEC 网站获取。内部人士持有公司 2.98% 的股票。</p>
<h2>机构资金流入和流出</h2>
<p>最近，一些机构投资者和对冲基金买卖了 DVAX 的股票。Osaic Holdings Inc.在第二季度将其在药明康德的持股增加了 15.1%。Osaic Holdings Inc.目前持有 9,336 股生物制药公司的股票，价值 93,000 美元，此前在该期间内又购买了 1,226 股。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.在第一季度将其在药明康德的持股增加了 1.9%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.目前持有 86,421 股生物制药公司的股票，价值 1,126,000 美元，此前在上个季度又购买了 1,625 股。E Fund Management Co. Ltd.在第二季度将其在药明康德的持股增加了 17.9%。E Fund Management Co. Ltd.目前持有 18,113 股生物制药公司的股票，价值 180,000 美元，此前在上个季度又购买了 2,752 股。Envestnet Asset Management Inc.在第三季度将其在药明康德的持股增加了 55.3%。Envestnet Asset Management Inc.目前持有 20,888 股生物制药公司的股票，价值 207,000 美元，此前在该期间内又购买了 7,441 股。最后，Tower Research Capital LLC TRC 在第二季度将其在药明康德的持股增加了 319.8%。Tower Research Capital LLC TRC 目前持有 16,239 股生物制药公司的股票，价值 161,000 美元，此前在上个季度又购买了 12,371 股。机构投资者和对冲基金持有公司 96.96% 的股票。</p>
<h2>分析师评级调整</h2>
<p>最近，一些券商对 DVAX 发表了评论。华尔街 Zen 在 8 月 9 日的报告中将药明康德的股票评级从 “持有” 上调至 “买入”。JMP Securities 在 8 月 22 日的报告中重申了 “市场表现优于大盘” 的评级，并对药明康德的股票设定了 32.00 美元的目标价。最后，Weiss Ratings 在 10 月 8 日的报告中重新发布了药明康德的 “卖出（d）” 评级。三位分析师对该股票给予了买入评级，两位分析师给予了卖出评级。根据 MarketBeat.com 的数据，药明康德目前的平均评级为 “持有”，共识目标价为 24.33 美元。</p>
<p><strong>获取我们关于 DVAX 的最新报告</strong></p>
<h2>药明康德公司简介</h2>
<p>（获取免费报告）</p>
<p>药明康德公司是一家商业阶段的生物制药公司，专注于在美国开发和商业化疫苗。它在美国和欧洲市场销售 HEPLISAV-B，这是一种用于预防所有已知亚型的乙型肝炎病毒感染的乙型肝炎疫苗，适用于 18 岁及以上人群。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票，而不是药明康德</li>
<li>使用 MarketBeat 股息收益计算器</li>
<li>目前有 3 只现金充裕的股票具有高增长潜力</li>
<li>揭示 VWAP 的力量：交易者的关键指标</li>
<li>为什么垂直航空股票在这次飞行测试后可能会翻倍</li>
<li>如何找到值得投资和交易的便士股票</li>
<li>亚马逊：突破确认——它可能接下来会去哪里</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFZBWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFZBWA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在药明康德吗？</h2>
<p>在你考虑药明康德之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前进行购买……而药明康德并不在名单上。</p>
<p>虽然药明康德目前在分析师中评级为持有，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

德纳维制药

<p>德纳维制药（NASDAQ:DVAX）报告的季度每股收益为 0.21 美元，超出预期 0.07 美元。该公司实现收入 9488 万美元，超过市场共识预期的 9400 万美元。尽管净利润率为负的 16.67%，但其股本回报率为正的 5.10%。股票交易价格为 10.30 美元，市值为 12.1 亿美元。分析师的评级意见不一，三位分析师推荐买入，二位分析师推荐卖出，平均目标价为 24.33 美元</p>

<p>Dynavax Technologies (NASDAQ:DVAX - Get Free Report) released its quarterly earnings results on Wednesday. The biopharmaceutical company reported $0.21 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.14 by $0.07, Zacks reports. The firm had revenue of $94.88 million for the quarter, compared to the consensus estimate of $94.00 million. Dynavax Technologies had a positive return on equity of 5.10% and a negative net margin of 16.67%.</p>
<div class="lb-trans"><p>药明康德（NASDAQ:DVAX - 获取免费报告）于周三发布了季度财报。这家生物制药公司报告本季度每股收益（EPS）为 0.21 美元，超出分析师一致预期的 0.14 美元，超出幅度为 0.07 美元，Zacks 报道。该公司本季度的收入为 9488 万美元，而一致预期为 9400 万美元。药明康德的股本回报率为 5.10%，净利润率为-16.67%。</p>
</div><p>Get <strong>Dynavax Technologies</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>药明康德</strong> 的提醒：</p>
</div><h2>Dynavax Technologies Stock Performance</h2>
<div class="lb-trans"><h2>药明康德股票表现</h2>
</div><p>NASDAQ DVAX traded up $0.25 during trading hours on Wednesday, hitting $10.30. 2,378,061 shares of the stock were exchanged, compared to its average volume of 1,977,836. Dynavax Technologies has a 12-month low of $9.20 and a 12-month high of $14.63. The stock has a 50-day moving average of $9.99 and a 200 day moving average of $10.28. The company has a market cap of $1.21 billion, a price-to-earnings ratio of -22.39 and a beta of 1.09. The company has a quick ratio of 6.01, a current ratio of 6.65 and a debt-to-equity ratio of 0.45.</p>
<div class="lb-trans"><p>周三，NASDAQ DVAX 在交易时段上涨 0.25 美元，达到 10.30 美元。该股票交易量为 2,378,061 股，而其平均交易量为 1,977,836 股。药明康德的 12 个月低点为 9.20 美元，12 个月高点为 14.63 美元。该股票的 50 日移动平均为 9.99 美元，200 日移动平均为 10.28 美元。公司的市值为 12.1 亿美元，市盈率为-22.39，贝塔值为 1.09。公司的速动比率为 6.01，流动比率为 6.65，债务股本比率为 0.45。</p>
</div><h2>Insider Transactions at Dynavax Technologies</h2>
<div class="lb-trans"><h2>药明康德的内部交易</h2>
</div><p>In other Dynavax Technologies news, Director Scott Dunseth Myers bought 3,800 shares of the business's stock in a transaction dated Friday, August 22nd. The stock was acquired at an average cost of $10.82 per share, with a total value of $41,116.00. Following the purchase, the director owned 35,004 shares in the company, valued at approximately $378,743.28. This represents a 12.18% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 2.98% of the company's stock.</p>
<div class="lb-trans"><p>在其他药明康德的新闻中，董事 Scott Dunseth Myers 于 8 月 22 日（星期五）购买了 3,800 股该公司的股票。该股票的平均购买价格为每股 10.82 美元，总价值为 41,116.00 美元。购买后，该董事在公司持有 35,004 股，估值约为 378,743.28 美元。这代表其持股比例增加了 12.18%。该交易已在向 SEC 提交的文件中披露，相关文件可通过 SEC 网站获取。内部人士持有公司 2.98% 的股票。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>A number of institutional investors and hedge funds have recently bought and sold shares of DVAX. Osaic Holdings Inc. lifted its holdings in Dynavax Technologies by 15.1% in the second quarter. Osaic Holdings Inc. now owns 9,336 shares of the biopharmaceutical company's stock valued at $93,000 after acquiring an additional 1,226 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Dynavax Technologies by 1.9% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 86,421 shares of the biopharmaceutical company's stock valued at $1,126,000 after purchasing an additional 1,625 shares in the last quarter. E Fund Management Co. Ltd. increased its holdings in shares of Dynavax Technologies by 17.9% in the 2nd quarter. E Fund Management Co. Ltd. now owns 18,113 shares of the biopharmaceutical company's stock valued at $180,000 after purchasing an additional 2,752 shares in the last quarter. Envestnet Asset Management Inc. lifted its stake in shares of Dynavax Technologies by 55.3% in the third quarter. Envestnet Asset Management Inc. now owns 20,888 shares of the biopharmaceutical company's stock valued at $207,000 after purchasing an additional 7,441 shares during the period. Finally, Tower Research Capital LLC TRC boosted its holdings in Dynavax Technologies by 319.8% during the second quarter. Tower Research Capital LLC TRC now owns 16,239 shares of the biopharmaceutical company's stock worth $161,000 after buying an additional 12,371 shares in the last quarter. Institutional investors and hedge funds own 96.96% of the company's stock.</p>
<div class="lb-trans"><p>最近，一些机构投资者和对冲基金买卖了 DVAX 的股票。Osaic Holdings Inc.在第二季度将其在药明康德的持股增加了 15.1%。Osaic Holdings Inc.目前持有 9,336 股生物制药公司的股票，价值 93,000 美元，此前在该期间内又购买了 1,226 股。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.在第一季度将其在药明康德的持股增加了 1.9%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.目前持有 86,421 股生物制药公司的股票，价值 1,126,000 美元，此前在上个季度又购买了 1,625 股。E Fund Management Co. Ltd.在第二季度将其在药明康德的持股增加了 17.9%。E Fund Management Co. Ltd.目前持有 18,113 股生物制药公司的股票，价值 180,000 美元，此前在上个季度又购买了 2,752 股。Envestnet Asset Management Inc.在第三季度将其在药明康德的持股增加了 55.3%。Envestnet Asset Management Inc.目前持有 20,888 股生物制药公司的股票，价值 207,000 美元，此前在该期间内又购买了 7,441 股。最后，Tower Research Capital LLC TRC 在第二季度将其在药明康德的持股增加了 319.8%。Tower Research Capital LLC TRC 目前持有 16,239 股生物制药公司的股票，价值 161,000 美元，此前在上个季度又购买了 12,371 股。机构投资者和对冲基金持有公司 96.96% 的股票。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级调整</h2>
</div><p>A number of brokerages have recently commented on DVAX. Wall Street Zen raised shares of Dynavax Technologies from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a report on Saturday, August 9th. JMP Securities reaffirmed a &#34;market outperform&#34; rating and issued a $32.00 target price on shares of Dynavax Technologies in a report on Friday, August 22nd. Finally, Weiss Ratings reissued a &#34;sell (d)&#34; rating on shares of Dynavax Technologies in a report on Wednesday, October 8th. Three analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Dynavax Technologies presently has an average rating of &#34;Hold&#34; and a consensus price target of $24.33.</p>
<div class="lb-trans"><p>最近，一些券商对 DVAX 发表了评论。华尔街 Zen 在 8 月 9 日的报告中将药明康德的股票评级从 “持有” 上调至 “买入”。JMP Securities 在 8 月 22 日的报告中重申了 “市场表现优于大盘” 的评级，并对药明康德的股票设定了 32.00 美元的目标价。最后，Weiss Ratings 在 10 月 8 日的报告中重新发布了药明康德的 “卖出（d）” 评级。三位分析师对该股票给予了买入评级，两位分析师给予了卖出评级。根据 MarketBeat.com 的数据，药明康德目前的平均评级为 “持有”，共识目标价为 24.33 美元。</p>
</div><p><strong>Get Our Latest Report on DVAX</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 DVAX 的最新报告</strong></p>
</div><h2>Dynavax Technologies Company Profile</h2>
<div class="lb-trans"><h2>药明康德公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.</p>
<div class="lb-trans"><p>药明康德公司是一家商业阶段的生物制药公司，专注于在美国开发和商业化疫苗。它在美国和欧洲市场销售 HEPLISAV-B，这是一种用于预防所有已知亚型的乙型肝炎病毒感染的乙型肝炎疫苗，适用于 18 岁及以上人群。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Dynavax Technologies</li>
<li>Using the MarketBeat Dividend Yield Calculator</li>
<li>3 Cash-Rich Stocks With High Growth Potential Right Now</li>
<li>Unveiling The Power Of VWAP: A Key Indicator For Traders</li>
<li>Why Vertical Aerospace Stock Could Double After This Flight Test</li>
<li>How to find penny stocks to invest and trade</li>
<li>Amazon: Breakout Confirmed—Here’s Where It Could Go Next</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是药明康德</li>
<li>使用 MarketBeat 股息收益计算器</li>
<li>目前有 3 只现金充裕的股票具有高增长潜力</li>
<li>揭示 VWAP 的力量：交易者的关键指标</li>
<li>为什么垂直航空股票在这次飞行测试后可能会翻倍</li>
<li>如何找到值得投资和交易的便士股票</li>
<li>亚马逊：突破确认——它可能接下来会去哪里</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFZBWA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=DVAX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Dynavax Technologies Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在药明康德吗？</h2>
</div><p>Before you consider Dynavax Technologies, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑药明康德之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dynavax Technologies wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前进行购买……而药明康德并不在名单上。</p>
</div><p>While Dynavax Technologies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然药明康德目前在分析师中评级为持有，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

德纳维制药（NASDAQ:DVAX）公布季度财报，每股收益超出预期 0.07 美元